Precirix Announces FDA Acceptance of Investigational New Drug (IND) Application for CAM-FAP-Ac-225

Brussels, Belgium, 24^th July 2025 — Precirix, a clinical-stage biopharmaceutical company focused on developing innovative targeted radiopharmaceutical therapies, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for CAM-FAP-Ac-225. This clearance enables Precirix to initiate a Phase 1 clinical trial in patients with FAP-positive tumors.

Full Press Release here +